Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

Inclusion Criteria: * Ability and willingness to provide written informed consent and adhere to study regimen. * Primary deceased donor liver transplant recipients 18-70 years of age * Functioning allograft at randomization (AST, ALT, Total Bilirubin levels ≤3 times ULN, and AlkP and GGT levels ≤ 5 times ULN). Elevated GGT alone, in combination with AST, ALT, total bilirubin and AlkP within defined range does not exclude patients from randomization. * Recipients on an immunosuppressive regimen of corticosteroids and tacrolimus. * Confirmed recipient HCV status at Screening (either by serology or PCR). * Abbreviated MDRD eGFR ≥ 30 mL/min/1.73m2. Local and central serum creatinine results within 5 days prior to randomization, however no sooner than Day 25 post-transplantation. * Verification of at least one tacrolimus trough level of ≥ 8 ng/mL one week prior to randomization. Target trough levels above 8 ng/mL prior to randomization. * Patients able to take oral medication at time of randomization. Exclusion Criteria: * Recipients of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant. Combined liver kidney transplant recipients. * Living donor or split liver recipients. * History of malignancy of any organ system within past 5 years whether or not there is evidence of local recurrence or metastases, other than non-metastatic basal or squamous cell carcinoma of the skin or HCC. * Hepatocellular carcinoma that does …